PeRiOperaTivE CardioproTection With Ivabradine in Non-cardiac Surgery

Inclusion Criteria: * Informed Consent as documented by signature of patient; AND * Undergoing intermediate or high-risk non-cardiac surgery (as defined in European Society of Anaesthesiology guidelines) AND; * One of the following: o≥ 75 years old OR; o≥ 45 years old AND at least 1 risk factors independently associated with perioperative myocardial injury (history of coronary artery disease, chronic heart failure, peripheral artery disease, ischemic stroke, hypertension, diabetes mellitus, chronic kidney disease). Exclusion Criteria: * Inability to provide informed consent; * History of hypersensitivity or allergy to ivabradine; * Emergency surgery (to be done within 24h of diagnosis); * Shock or acute decompensated heart failure at trial inclusion; * Low cardiac output syndrome; * Arrhythmia: * Atrial fibrillation or flutter; * AV-block of 3rd degree; * Sick sinus syndrome; * Sino-atrial block; * Pacemaker dependency; * Unstable angina; * Acute myocardial infarction in the 3 months preceding the trial; * Stroke in the 3 months preceding the trial; * Cirrhosis Child B and C; * Renal failure with a Estimated Glomerular filtration rate ≤ 15 ml/min/1.73m2; * Treatment with a strong cytochrome P450 3A4 inhibitors such as azole antifungals (ketoconazole, itraconazole), macrolide antibiotics (clarithromycin, erythromycin; josamycin, telithromycin), HIV protease inhibitors (nelfinavir, ritonavir) and nefazodone; * Treatment with verapamil or diltiazem which are moderate CYP3A4 inhibitors and PGP inducers with heart rate reducing properties; * Women who are pregnant or breast feeding; * Childbearing potential (Of note, woman with history of hysterectomy, surgical sterilization or menopause for longer than 2 years are not considered with childbearing potential, independent of their age); * Participation in another study with investigational drug within the 30 days preceding and during the present study; * Previous enrolment into the current study.